Genomic Valley Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 15/10/2025 ,inter alia, to consider and approve The unaudited financial ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Genomic Valley Biotech Ltd has informed BSE that its Board of Directors will meet on Wednesday, 15 October 2025 at the registered office. The main agenda is to consider and approve the unaudited standalone financial results for the quarter and half year ended 30 September 2025. The company has also stated that any other business items may be taken up with the Chairman's permission. As per insider trading regulations, the trading window for directors, KMPs, promoters, and designated persons is closed from 1 October 2025 until 48 hours after the results are made public. The intimation is filed under Regulation 29 of SEBI LODR Regulations, 2015.
This is a routine pre-results intimation with no new financial information disclosed. Shareholders should watch for the actual Q2/H1 FY26 results on 15 October 2025, which will give the first read on the company's performance for the period.